<br>Serum IgA, IgG, and IgG subclass responses specific for (A) OMV, (B) Ptx, (C) Prn, (D) FHA, and (E) Fim2/3 were determined by using a MIA. Data were obtained in naive mice and protected mice prior to challenge (D0) and 14 days post infection (p.i.) or 14 days post-challenge (p.c.) (n=3/time point). (F) Pulmonary IgA responses against these antigens were determined on the same time points. * = p<0.05 experimental group versus unprotected group (D0), + = p<0.05 protected group (D0) versus protected group (14 days p.c.). (G) The kinetics of the anti-OMV IgA antibody formation in lung lysates were analyzed at more time points (n=3/time point) and expressed in fluorescence intensity (F.I.). **** = p<0.0001, challenged unprotected or protecte...
<p>(A–E) Antibody titers elicited by vaccination with DM-C. Six mice per groups were vaccinated with...
Injected with 1/5 human dose (HD) wP, aP, or adjuvant (C), twice before intranasal infection. Three ...
Injected with 1/5 human dose (HD) wP, aP, or adjuvant (C), twice before intranasal infection. Three ...
<p>Serum IgA, IgG, and IgG subclass responses specific for (A) OMV, (B) Ptx, (C) Prn, (D) FHA, and (...
<br>(A) Schematic diagram of animal pre-treatment, sacrifice, sampling and systems analysis on 4 hou...
<p>Antibody responses were determined in mouse sera after intranasal infection by whole cell <i>B. p...
<p>The binding of serum (<b>A</b>) and nasal lavage (<b>B</b>) IgG antibodies to Bvg<sup>+</sup> or ...
Worldwide resurgence of pertussis necessitates the need for improvement of pertussis vaccines and va...
<p>Merging data from a wide array of functional analyses reveals a comprehensive overview of the imm...
<div><p>Worldwide resurgence of pertussis necessitates the need for improvement of pertussis vaccine...
<p>Mice were immunized with whole cell pertussis vaccine (<i>Bordetella pertussis</i>) and antigen-s...
Uvant (C), twice before intranasal infection. Two hours before challenge, and three and seven days a...
<p>Groups of four mice were either (A–D) uninfected or inoculated with <i>B. pertussis</i> and eutha...
<p>(A) The serum concentrations of 33 cytokines were analyzed before and after a <i>B</i>. <i>pertus...
The results of phase 3 efficacy trials have shown that acellular and whole-cell pertussis vaccines c...
<p>(A–E) Antibody titers elicited by vaccination with DM-C. Six mice per groups were vaccinated with...
Injected with 1/5 human dose (HD) wP, aP, or adjuvant (C), twice before intranasal infection. Three ...
Injected with 1/5 human dose (HD) wP, aP, or adjuvant (C), twice before intranasal infection. Three ...
<p>Serum IgA, IgG, and IgG subclass responses specific for (A) OMV, (B) Ptx, (C) Prn, (D) FHA, and (...
<br>(A) Schematic diagram of animal pre-treatment, sacrifice, sampling and systems analysis on 4 hou...
<p>Antibody responses were determined in mouse sera after intranasal infection by whole cell <i>B. p...
<p>The binding of serum (<b>A</b>) and nasal lavage (<b>B</b>) IgG antibodies to Bvg<sup>+</sup> or ...
Worldwide resurgence of pertussis necessitates the need for improvement of pertussis vaccines and va...
<p>Merging data from a wide array of functional analyses reveals a comprehensive overview of the imm...
<div><p>Worldwide resurgence of pertussis necessitates the need for improvement of pertussis vaccine...
<p>Mice were immunized with whole cell pertussis vaccine (<i>Bordetella pertussis</i>) and antigen-s...
Uvant (C), twice before intranasal infection. Two hours before challenge, and three and seven days a...
<p>Groups of four mice were either (A–D) uninfected or inoculated with <i>B. pertussis</i> and eutha...
<p>(A) The serum concentrations of 33 cytokines were analyzed before and after a <i>B</i>. <i>pertus...
The results of phase 3 efficacy trials have shown that acellular and whole-cell pertussis vaccines c...
<p>(A–E) Antibody titers elicited by vaccination with DM-C. Six mice per groups were vaccinated with...
Injected with 1/5 human dose (HD) wP, aP, or adjuvant (C), twice before intranasal infection. Three ...
Injected with 1/5 human dose (HD) wP, aP, or adjuvant (C), twice before intranasal infection. Three ...